Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 5, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Prognostic heterogeneity in ASXL1-mutated AML and refinement by an immunophenotype-based score.

Yaming Zhang1, Min Zhang2, Yali Huang1

  • 1Department of Hematology, Key Laboratory of Hematological Malignancies at Affiliated Hospital of Guizhou Medical University, Guiyang, China.

Frontiers in Oncology
|June 4, 2026
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comments on "Preventive Effect of Helicobacter pylori Treatment on Gastric Cancer Incidence and Mortality: A Korean Population Study".

Gastroenterology·2025
Same author

TPF regimen improves conversion surgery and short-term survival in patients with locally unresectable advanced gastric cancer.

American journal of translational research·2025
Same author

Effect of the Microstructure of Carbon Supports on the Oxygen Reduction Properties of the Loaded Non-Noble Metal Catalysts.

Nanomaterials (Basel, Switzerland)·2025
Same author

TEA domain transcription factor 3 suppresses aortic and left ventricular remodeling via transcriptional activation of PDZ domain containing 1.

Biochemical pharmacology·2025
Same author

Prospects and challenges of salivary gland tissue engineering in Sjögren's syndrome.

Expert reviews in molecular medicine·2025
Same author

Correction: Overexpression of Nrf2 in bone marrow mesenchymal stem cells promotes B-cell acute lymphoblastic leukemia cells invasion and extramedullary organ infiltration through stimulation of the SDF-1/CXCR4 axis.

Frontiers in pharmacology·2025

ASXL1 mutations in acute myeloid leukemia (AML) are not uniformly high-risk. An ImmuScore based on immunophenotypic markers effectively stratifies prognosis and predicts treatment response in AML patients.

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • ASXL1 mutations are common in acute myeloid leukemia (AML) and typically indicate a poor prognosis.
  • However, the clinical impact of ASXL1 mutations in AML is highly variable.

Purpose of the Study:

  • To investigate the heterogeneity of clinical outcomes in ASXL1-mutated AML.
  • To identify biological and immunophenotypic factors associated with treatment response and resistance.
  • To develop a prognostic tool for ASXL1-mutated AML.

Main Methods:

  • Integrated analysis of genomic, transcriptomic, immunophenotypic, and drug-sensitivity data from the BeatAML cohort.
  • Multivariable analyses to assess ASXL1 as an independent prognostic factor.
  • Stratification of ASXL1-mutated patients based on treatment response (complete remission vs. relapsed/refractory).
Keywords:
ASXL1acute myeloid leukemia (AML)immuScoremutationrisk

More Related Videos

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

Related Experiment Videos

Last Updated: Jun 5, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

  • Development and validation of a three-parameter ImmuScore using routinely measured markers.

    • Main Results:

    • ASXL1 mutations were an independent adverse factor, but prognosis varied significantly.
    • Two distinct subsets of ASXL1-mutated AML were identified: complete remission and relapsed/refractory.
    • Relapsed/refractory patients showed distinct transcriptional profiles and downregulation of CD11b, CD123, and HLA-DR.
    • The ImmuScore accurately stratified prognosis in both discovery and validation cohorts.
    • Low ImmuScore correlated with reduced sensitivity to multiple chemotherapeutic and targeted agents.

    Conclusions:

    • ASXL1-mutated AML is not a single high-risk entity; distinct subsets exist.
    • Immunophenotypic signatures are linked to therapeutic vulnerability in ASXL1-mutated AML.
    • The ImmuScore is a clinically feasible tool to identify high-risk ASXL1-mutated AML patients for personalized therapy.